News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,914 Results
Type
Article (43875)
Company Profile (310)
Press Release (675729)
Section
Business (212193)
Career Advice (2181)
Deals (37080)
Drug Delivery (113)
Drug Development (84110)
Employer Resources (174)
FDA (16676)
Job Trends (15556)
News (359628)
Policy (34380)
Tag
Academia (2613)
Alliances (51959)
Alzheimer's disease (1344)
Approvals (16645)
Artificial intelligence (222)
Bankruptcy (373)
Best Places to Work (11843)
Biotechnology (195)
Breast cancer (231)
Cancer (1774)
Cardiovascular disease (142)
Career advice (1813)
CAR-T (129)
Cell therapy (365)
Clinical research (67714)
Collaboration (696)
Compensation (381)
COVID-19 (2660)
C-suite (164)
Data (1648)
Diabetes (223)
Diagnostics (6399)
Earnings (87570)
Employer resources (152)
Events (114949)
Executive appointments (582)
FDA (17599)
Funding (620)
Gene therapy (263)
GLP-1 (725)
Government (4551)
Healthcare (19101)
Infectious disease (2781)
Inflammatory bowel disease (126)
Interviews (339)
IPO (16901)
Job creations (4160)
Job search strategy (1553)
Layoffs (478)
Legal (8503)
Lung cancer (265)
Manufacturing (253)
Medical device (13398)
Medtech (13403)
Mergers & acquisitions (20555)
Metabolic disorders (606)
Neuroscience (1774)
NextGen: Class of 2025 (6723)
Non-profit (4551)
Northern California (2105)
Obesity (343)
Opinion (237)
Patents (170)
People (59324)
Phase I (21097)
Phase II (29766)
Phase III (22271)
Pipeline (727)
Postmarket research (2684)
Preclinical (8859)
Radiopharmaceuticals (250)
Rare diseases (345)
Real estate (6357)
Regulatory (23124)
Research institute (2384)
Resumes & cover letters (370)
Southern California (1804)
Startups (3785)
United States (18791)
Vaccines (646)
Weight loss (255)
Date
Today (93)
Last 7 days (621)
Last 30 days (2718)
Last 365 days (35377)
2025 (4592)
2024 (36149)
2023 (40930)
2022 (52113)
2021 (56675)
2020 (55109)
2019 (47821)
2018 (36140)
2017 (33570)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30872)
2010 (28890)
Location
Africa (807)
Arizona (220)
Asia (41372)
Australia (6573)
California (4813)
Canada (1730)
China (409)
Colorado (220)
Connecticut (232)
Europe (88570)
Florida (701)
Georgia (165)
Illinois (470)
Indiana (273)
Maryland (759)
Massachusetts (3681)
Michigan (200)
Minnesota (338)
New Jersey (1373)
New York (1369)
North Carolina (883)
Northern California (2105)
Ohio (176)
Pennsylvania (1107)
South America (1181)
Southern California (1804)
Texas (716)
Utah (147)
Washington State (476)
719,914 Results for "shionogi pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia
December 18, 2024
·
6 min read
Press Releases
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
October 1, 2024
·
5 min read
Business
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.
April 30, 2024
·
9 min read
Business
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.
May 10, 2024
·
6 min read
Press Releases
Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder
February 4, 2025
·
10 min read
Press Releases
Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma
February 20, 2025
·
2 min read
Press Releases
Vincerx Pharma, Inc. Announces Reverse Stock Split
January 23, 2025
·
4 min read
Business
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.
February 26, 2024
·
7 min read
Press Releases
Shionogi Receives Award Through BARDA’s Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations
January 16, 2025
·
4 min read
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
Shionogi & Co., Ltd. announced the company is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in the U.S., in San Diego, California.
June 3, 2024
·
9 min read
1 of 71,992
Next
